Janssen’s HIV Drug Symtuza to Join NHI Price List on July 3

June 27, 2019
Janssen Pharmaceutical’s quadruple HIV drug Symtuza (darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)) will be added to the NHI reimbursement price list on July 3. The listing was endorsed by the Central Social Insurance Medical Council, a key...read more